Efficacy of bevacizumab maintenance therapy in advanced ovarian cancer

This study aimed to evaluate the efficacy of bevacizumab maintenance therapy in advanced ovarian cancer and its impact on the Janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3)/vascular endothelial growth factor A (VEGFA) pathway. A total of 126 patients were enrolled, divided into two groups: control (n=62) and study (n=64). The control group received neoadjuvant chemotherapy, tumor debulking surgery, and postoperative adjuvant chemotherapy. The research group received postoperative bevacizumab maintenance therapy in addition to standard treatment. Results showed that the research group had significantly improved disease control rates (43.75% vs. 24.19%, P=0.0206), objective response rates (76.56% vs. 48.39%, P=0.0011), overall survival (30.45±7.69 months vs. 22.92±7.26 months, P<0.0001) and progression-free survival (16.08±2.46 months vs. 12.08±2.25 months) compared to controls. Bevacizumab also led to lower levels of Janus kinase 2 (JAK2), signal transducer and activator of transcription 3 (STAT3) and vascular endothelial growth factor A (VEGFA) expression. This therapy demonstrated safety and efficacy, significantly prolonging progression-free survival and overall survival.